Unicycive Q3 net loss $4.1M; OLC NDA accepted with PDUFA June 2025

Unicycive Therapeutics, Inc.

2024-Q3 EPS reported -$0.30

Net loss $4.1M vs $4.4M YoY; cash $32.3M expected to fund into 2026.
FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.
OLC patient survey: 79% preferred OLC over prior therapy; 98% said easy to take.
UNI-494 Phase 1 completed; plans to request FDA meeting by end of 2024.
Added to Russell Microcap Index effective July 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.